STRATEGIC NEWS WATCH — July 17, 2026
|
The FDA converted Novartis’ Fabhalta to full approval in IgA nephropathy on the strength of a two-year kidney-function benefit, anchoring a regulation-heavy day in which the agency also disavowed its former officials’ journal papers and flagged renewed manufacturing concerns at Novo Nordisk and Alvotech plants. Today’s top developments:
|
What to Watch
- Novartis IgAN franchise build-out — With Fabhalta now fully approved alongside accelerated-approval Vanrafia, the interim eGFR readout for the Phase 3 anti-APRIL antibody zigakibart, expected in the first half of 2027, becomes the next catalyst; watch how Travere’s Filspari and Calliditas’s Tarpeyo defend share.
- FDA policy normalization — Having disavowed the Makary and Prasad journal papers, the agency’s move to codify the “plausible mechanism pathway” and CAR-T randomized-trial expectations through formal guidance under acting director Kyle Diamantas will signal whether prior-leadership uncertainty is easing.
- Novo & Alvotech manufacturing remediation — Both companies must show the FDA credible corrective-action plans; further deficiencies at the flagged plants could trigger warning letters or import alerts and delay revenue-driving approvals.
- Jasper–Kira integration execution — The combined company’s ability to advance Kira’s immune-mediated pipeline on Jasper’s public-market vehicle is the real test; any early pipeline setback would quickly undercut the deal rationale.
- China cross-border BD capability — As competition for best-in-class Chinese assets intensifies, dealmakers building China-fluent relationship and deal-structuring expertise will hold a widening structural advantage over rivals that treat it as an afterthought.
This brief highlights the edition’s top stories. Read the full July 17, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.